Clinic Rollup & Dental Service Organization (DSO) Valuation

Who this is for

PE-backed DSO and clinic rollup operators evaluating platform value and add-on targets, and independent practice owners considering joining a DSO platform or selling to a strategic acquirer.

What drives value in Clinic Rollup / DSO

  • Number of sites and same-store EBITDA growth across locations
  • De novo opening track record and pipeline of signed LOIs
  • Associate provider density and non-compete provisions
  • Specialty mix: general practice versus higher-margin specialties (ortho, endo, perio)
  • Insurance credentialing breadth and commercial payer contract terms
  • Central services infrastructure reducing per-site overhead

Valuation methods we use

DSOs and clinic platforms are valued at 8–16× EBITDA, with larger platforms commanding the high end due to central services leverage and de novo optionality. Individual practices acquired by DSOs typically trade at 4–7× EBITDA. This tool is informational only. Output is driven by your inputs and does not constitute a formal appraisal or certified valuation.

Disclaimer: ValueAlpha is an AI-powered estimation tool. All outputs are informational only, driven entirely by your inputs. This is not a formal appraisal, certified valuation, or investment advice. For a formal valuation opinion, engage a qualified business appraiser.

Typical metrics and inputs

Site-level EBITDA margin

Four-wall EBITDA per location; the primary measure of individual practice health.

De novo success rate

Percentage of new clinics reaching target EBITDA within 24 months; key platform scalability signal.

Collections per provider day

Daily production collections per active provider; benchmarked to specialty norms.

Same-store EBITDA growth

Year-over-year EBITDA growth at locations open 18+ months.

Associate-to-owner ratio

Number of associate providers per partner; higher ratio increases platform scalability.

Example scenarios

20-location dental DSO

A DSO with 20 locations, $8 M platform EBITDA, and a proven de novo playbook might be valued at 12–15× EBITDA in a PE secondary.

Single-specialty optometry rollup

A 10-location optometry platform with $3 M EBITDA and strong commercial payer mix might trade at 9–11× EBITDA.

Frequently asked questions

What multiple does a DSO sell for?

Platform DSOs with 10+ sites: 10–16× EBITDA. Individual dental practices selling into a DSO: 4–7× EBITDA.

Why do DSO platforms get higher multiples than individual practices?

Central services reduce per-site costs, de novo pipelines create growth optionality, and platform infrastructure reduces key-person risk — all commanding premium multiples.

How are de novo openings valued?

A proven de novo playbook adds significant option value. Buyers model the NPV of future site openings based on historical ramp-to-profitability timelines.

What specialties command the highest multiples in dental?

Orthodontics and oral surgery typically earn higher multiples than general dentistry due to higher margins and more predictable case mix.

Is this a certified appraisal?

No. This tool provides informational estimates. For DSO M&A, engage a healthcare-focused M&A advisor.

Run your Clinic Rollup / DSO valuation

Get a professional-grade valuation report using DCF, comparable companies, precedent transactions, and scenario analysis — for just $9.99.

Join the waitlist →